Sandoz has announced that WYOST and Jubbonti are available to patients in the US. WYOST and Jubbonti are the first and only interchangeable FDA-approved denosumab biosimilars and are approved to treat all indications of the reference medicines XGEVA and Prolia, respectively. The company noted that WYOST and Jubbonti have the same dosage form, route of administration, dosing regimen and presentation as the respective reference medicines.
Sandoz said it is providing comprehensive support resources for patients who are prescribed WYOST and Jubbonti, including reimbursement and financial support.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.